Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

11018	Companies
241409	Keywords
169912	Articles
129949	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 12/16/2024 at 15:00, 1 year 9 months ago

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Xenetic Biosciences extends Research Funding Agreement with UVA to develop systemic DNase program targeting NETs to improve cancer therapy outcomes

Xenetic Biosciences DNase Program Cancer Therapy Immunotherapy NETs
BRIEF

published on 12/05/2024 at 14:50, 1 year 9 months ago

Xenetic Biosciences s'associe à PeriNess pour les services d'essais cliniques

Essais Cliniques Oncologie Biosciences Xénétiques ADNase I PeriNess Ltée.
BRIEF

published on 12/05/2024 at 14:50, 1 year 9 months ago

Xenetic Biosciences Partners with PeriNess for Clinical Trial Services

Xenetic Biosciences Clinical Trials Oncology DNase I PeriNess Ltd.
PRESS RELEASE

published on 12/05/2024 at 14:45, 1 year 9 months ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Xenetic Biosciences partners with PeriNess to advance clinical proof-of-concept studies for systemic DNase I treatment in pancreatic and colorectal cancers. Collaboration aims to leverage expertize and improve therapeutic responses

Xenetic Biosciences Clinical Development Pancreatic Cancer PeriNess Systemic DNase I
BRIEF

published on 11/22/2024 at 15:20, 1 year 9 months ago

Xenetic Biosciences Shares Insights on DNase I Efficacy in Cancer Treatment

Xenetic Biosciences Cancer Treatment Preclinical Data DNase I Immune Checkpoint Blockade
BRIEF

published on 11/22/2024 at 15:20, 1 year 9 months ago

Xenetic Biosciences partage ses connaissances sur l'efficacité de la DNase I dans le traitement du cancer

Traitement Du Cancer Biosciences Xénétiques Données Précliniques ADNase I Blocage Du Point De Contrôle Immunitaire
PRESS RELEASE

published on 11/22/2024 at 15:15, 1 year 9 months ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, presents positive preclinical data at SITC 39th Annual Meeting. Focus on advancing immune-oncology technologies to treat hard cancers

Cancer Treatment Preclinical Data Immunotherapy SITC 39th Annual Meeting Dr. Reid Bissonnette
BRIEF

published on 11/21/2024 at 14:35, 1 year 9 months ago

Xenetic Biosciences annonce des résultats précliniques prometteurs pour la thérapie par ADNase I et cellules CAR T dans le mélanome

Étude Préclinique Mélanome ADNase I Cellules CAR-T Thérapie Oncologique
BRIEF

published on 11/21/2024 at 14:35, 1 year 9 months ago

Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Preclinical Study Melanoma DNase I CAR T Cells Oncology Therapy
PRESS RELEASE

published on 11/21/2024 at 14:30, 1 year 9 months ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic presents preclinical data on DNase I and CAR T cells' synergistic effects in treating solid tumors. Results show promise in modulating tumor microenvironment and enhancing therapeutic responses

Preclinical Data Solid Tumors Xenetic DNase I CAR T Cells

Accesswire

Published on 09/17/2026 at 15:55, 4 hours 12 minutes ago

Empress Announces Agreement to Acquire Tongon Gold Stream and Secures Debt Financing
Published on 09/17/2026 at 15:25, 4 hours 42 minutes ago

AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare
Published on 09/17/2026 at 15:00, 5 hours 7 minutes ago

Norsemont Hits 41 Meters of 4.59 g/t Gold as Phase 3 Drilling Continues to Expand the Choquelimpie System
Published on 09/17/2026 at 15:00, 5 hours 7 minutes ago

ECC Ventures 4 Announces Termination of Agreement With Cambria Gold Mines Inc.
Published on 09/17/2026 at 14:50, 5 hours 17 minutes ago

Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner

View all ACCESSWIRE

EQS Group

Published on 09/17/2026 at 19:00, 1 hour 6 minutes ago

Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Published on 09/17/2026 at 18:58, 1 hour 8 minutes ago

EQS-Adhoc: H2APEX Group SCA: General Partner of H2APEX Group SCA resolves to prepare for the transfer of its stock exchange listing from the Regulated Market (Prime Standard) to the Scale segment of the Frankfur
Published on 09/17/2026 at 18:25, 1 hour 41 minutes ago

Magentic raises $18M to build the AI workforce for the physical world
Published on 09/17/2026 at 18:10, 1 hour 56 minutes ago

A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%
Published on 09/17/2026 at 17:46, 2 hours 20 minutes ago

RBI categorically denies the allegations of short-seller report

Les Echos

Published on 09/17/2026 at 18:10, 1 hour 57 minutes ago

Rapport semestriel 2026
Published on 09/17/2026 at 17:40, 2 hours 27 minutes ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/17/2026 at 17:40, 2 hours 27 minutes ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 23 hours 20 minutes ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 18:45, 1 day 1 hour ago

STEF : Droits de vote au 31 08 2026

View all LES ECHOS COMFI WIRE